A Tethered Ligand Assay to Probe the SARS-CoV-2 ACE2 Interaction under Constant Force
M. S. Bauer, S. Gruber, L. F. Milles, T. Nicolaus, L. C. Schendel, H. E. Gaub, J. Lipfert
Abstract
The current COVID-19 pandemic has a devastating global impact and is caused by the SARS-CoV-2 virus. SARS-CoV-2 attaches to human host cells through interaction of its receptor binding domain (RBD) located on the viral Spike (S) glycoprotein with angiotensin converting enzyme-2 (ACE2) on the surface of host cells. RBD binding to ACE2 is a critical first step in SARS-CoV-2 infection. Viral attachment occurs in dynamic environments where forces act on the binding partners and multivalent interactions play central roles, creating an urgent need for assays that can quantitate SARS-CoV-2 interactions with ACE2 under mechanical load and in defined geometries. Here, we introduce a tethered ligand assay that comprises the RBD and the ACE2 ectodomain joined by a flexible peptide linker. Using specific molecular handles, we tether the fusion proteins between a functionalized flow cell surface and magnetic beads in magnetic tweezers. We observe repeated interactions of RBD and ACE2 under constant loads and can fully quantify the force dependence and kinetics of the binding interaction. Our results suggest that the SARS-CoV-2 ACE2 interaction has higher mechanical stability, a larger free energy of binding, and a lower off-rate than that of SARS-CoV-1, the causative agents of the 2002-2004 SARS outbreak. In the absence of force, the SARS-CoV-2 RBD rapidly (within [≤]1 ms) engages the ACE2 receptor if held in close proximity and remains bound to ACE2 for 400-800 s, much longer than what has been reported for other viruses engaging their cellular receptors. We anticipate that our assay will be a powerful tool investigate the roles of mutations in the RBD that might alter the infectivity of the virus and to test the modes of action of neutralizing antibodies and other agents designed to block RBD binding to ACE2 that are currently developed as potential COVID-19 therapeutics.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A Tethered Ligand Assay to Probe SARS-CoV-2:ACE2 Interactions
M. S. Bauer, S. Gruber, … J. Lipfert·bioRxiv·Aug 8, 2021
- Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction
W. Cao, C. Dong, … X. F. Zhang·bioRxiv·Jul 31, 2020
- Identifying Key Determinants of SARS-CoV-2/ACE2 Tight Interaction
- Critical Interactions Between the SARS-CoV-2 Spike Glycoprotein and the Human ACE2 Receptor
E. Taka, S. Z. Yilmaz, … M. Gur·bioRxiv·Sep 21, 2020
- Modulation of SARS-CoV-2 spike binding to ACE2 throughconformational selection
Prithwidip Saha, Ignacio Fernandez, … Félix Rico·Nature NanotechnologyPeer-reviewed·Jun 10, 2025
- SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection
A. E. Chaouat, H. Achdout, … O. Mandelboim·bioRxiv·Apr 18, 2021